Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Dare Bioscience (DARE) over the last 8 years, with Q3 2025 value amounting to $1.0 million.

  • Dare Bioscience's Non-Current Deffered Revenue changed 0.0% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.0 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Dare Bioscience reported Non-Current Deffered Revenue of $1.0 million as of Q3 2025, which was down 0.0% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Non-Current Deffered Revenue registered a high of $1.2 million during Q2 2023, and its lowest value of $1.0 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $1.0 million (2021), whereas its average is $1.0 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 2052.06% in 2023, then tumbled by 1702.66% in 2024.
  • Quarter analysis of 5 years shows Dare Bioscience's Non-Current Deffered Revenue stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $1.0 million for Q3 2025, versus $1.0 million for Q2 2025 and $1.0 million for Q1 2025.